A serum-less medium for use in the growth of cells. The medium is an improved aqueous culture media of the MEM type comprising thyroxin, insulin, and Vitamin A. Hydrocortisone and essential fatty acids may also be advantageously used, as may effective quantities of Vitamin E. Surfactants are used to make the vitamins and any fatty acids available for cell growth. This aqueous media may also comprise cell-growth-enhancing quantities of biotin and folic acids.
|
1. An MEM zinc option A cell culturing medium wherein the amino acid profile is about as follows:
7. An aqueous culture media for use in cell growth having about the following formula:
11. An improved process for growing lines of living cells comprising the steps of growing said cells in a growth medium, through at least two passages, said medium an a modified MEM zinc option type medium having about the following amino acid profile:
2. An MEM zinc option A medium, as defined in
3. A culture media as defined in
4. A culture media as defined in
6. A culture media as defined in
8. A culture media as defined in
9. A medium as defined in
10. A medium as defined in
12. A process as defined in
biotin folic acid Thyroxine Insulin Hydrocortisone Essential Fatty Acids Vitamin A Vitamin E Surfactants
13. A process as defined in
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation-in-part of application Ser. No. 951,500 filed Oct. 6, 1978 which was a continuation-in-part of application Ser. No. 866,338 filed Jan. 1, 1978, both now abandoned.
This invention relates to a novel cell growing medium and novel process for growing living cells.
Over the years there has been a substantial amount of effort directed to the problem of providing a versatile and efficacious culture media from reproducible, fully-characterized components. This "ideal" approach is frequently compromised with respect to the "fully characterized" nature of the components. For example, much work has been done (e.g. as described in U.S. Pat. Nos. 3,128,228 by J. Michl and 3,953,290 by K. Uthne) describing the use of serum of blood fractions in cell culture media. However, these fractions have some of the disadvantages of whole serum and other bulk protein sources. They are not as fully characterized as is desirable; that is, they will differ from batch to batch and introduce unknown variables in the media. Such variables can affect the growth of cells and can do so in wholly umpredictable ways.
Other workers have recognized the value of culture media which is free of serum and other bulk protein supplements which can interfere with cell replication. To date, some of these attempts have proved partially successful. Although the media developed in each case has serious limitations.
Thus, Torney et al in U.S. Pat. No. 3,887,930 and U.S. Pat. No. 4,055,460 describes a media containing a particulate resin which provides an undesirable substrate on which cells can grow and from which their removal can be difficult.
The work described by Bower, Arthur and Fine, Propagation of mouse mammary tumor cell lines and production of mouse mammary tumor virus in a serum free media, in In Vitro (Pages 558-563, Volume 12, No. 8, 1976), utilizes a media containing considerable amounts of ethyl alcohol and lipids. The high volatility of ethyl alcohol (much higher than that of the acqueous media), which is used in this media to disperse the lipids in the acqueous solution, predisposes their media to serious problems. Gradual evaporation of the alcohol must be expected in the conditions to be found in cell culture incubators (about 37°C with a variable CO2 concentration in the atmosphere), causing their media to separate into a biphasic (lipid-acqueous) mixture. This type of mixture would not be appropriate for most cell culture work, nor would its exact composition be easily regulated. Besides, high concentration of alcohol, by itself, may have undesirable effects upon cell growth in many situations.
Other work, as described by S. T. Donta in "The growth of functional rat glial cells in a serumless medium." in Experimental Cell Research (Pages 119-124, Volume 82, 1973), has succeeded in adapting a single, specialized cell line to grow in a chemically defined media without bulk protein supplementation. However, this media has been unable to support the growth of other cell lines, unless used in combination with albumin. Thus, the media is not versatile unless supplemented with proteins which are not fully characterized.
Still another work, as described in U.S. Pat. No. 4,049,494, relates to processes for growing cells in serum-less media wherein the cells are from cell lines which have been specially adapted to function in the media. Such processes and media, of course, are lacking in broad utility. U.S. Pat. No. 4,072,565 describes the use of protamine zinc insulin in processes limited to short-terms by limitations inherent in the media selected.
Therefore, even after one decides on the ideal of providing a serum-free media, it is a further problem to provide a media with a combination of nutrients versatile with respect to a cell type that can be grown in it. Also, these nutrients, once identified, must be made available to the cells in a controlled fashion, without the introduction of highly volatile components of biphasic mixtures of variable composition. Furthermore, such a media must be free of particulate elements which would introduce unwarranted growth surfaces. Finally, this media should not be supplemented with partially refined bulk protein sources.
It is a principal object of the invention to provide an improved aqueous culture medium for growing cells.
It is a particular object of the invention to provide a culture medium that is fully characterized and, consequently, subject to accurate replication without dependence on animal blood serums or on other non-characterized materials, e.g. the bulk protein supplements commonly used in the art.
A further object of the invention is to provide a culture media described in the foregoing objects which comprises specific combinations of vitamins, fatty acids, and hormones to enhance cellular growth and which is substantially free of volatile or particulate components.
Still another object of the invention is to provide an improved basic culture media, one which is not necessarily optimized with respect to specific nutrients, but which is a substantial improvement over minimum essential media (MEM), including those of the zinc option type, known to the art.
A further object of the invention is to provide cell growth media of improved shelf life and versatility.
Another object of the invention is to provide an improved process utilizing the valuable features of the culture media of the invention.
Further objects of the invention include providing specific combinations of cell-growth materials in such a way as to make them readily available to growing cells over an extended period of time.
Other objects of the invention will be obvious to those skilled in the art on their reading this disclosure.
The above objects have been substantially achieved by (a) the development of an improved basic culture media of the MEM-zinc option type. In the more advantageous forms of the invention, an improved basic media is enhanced with hormones such as thyroxine, and insulin and Vitamin A. It is also advantageous to add hydrocortisone and essential fatty acids such as linoleic, linolenic and arachidonic acids. Vitamin E is also a desirable additive. In each case an acceptably water-dispersable, physiologically-equivalent compound such as physiologically equivalent salts, isomers, homologues, polymers, or other derivatives may be utilized. In general, the physiological equivalents are well known to the art.
It is to be emphasized that the process and media of the instant invention is useful with a wide variety of cells without special selective breeding products to build up a special adaption to the serum. Moreover, the cell growth can be prolonged over periods of three months or more in many advantageous modes of the invention.
One basic medium, found advantageous by itself and also advantageous for use as a base for a selective augmentation, is formed with substantial quantities of amino acids, biotin and folic acid. This basic medium, fortified to achieve an improved amino acid profile and fortified with the indicated vitamins, provides a growth culture media of improved versatility and performance.
To form the preferred growth media of the invention, the following are to be added to the fortified basic medium as described above.
Thyroxine: preferably T4 but T3 could also be used. The material is available in many commercial forms, including salt forms. Quantities of T4 from 0.01 to 0.03 micrograms per liter are desirable.
Insulin: A quantity of about 4 milligrams per liter is used.
Hydrocortsone: Again, this material is available in many forms. What is essential is to have a cortisone-active nucleus. A quantity of from about 0.075 to 0.3 milligrams per liter is preferred.
Essential Fatty Acids: The preferred acids are linoleic, linolenic and arachidonic. Although not water soluble, these materials are so emulsified with an appropriate surfactant as to become distributed in the aqueous medium in such a way that their molecules are readily available to the cell-growing population even in the preferred aqueous growth media. A quantity of from about 2.5 to 15 milligrams per liter is required.
Vitamin E and Vitamin A: Vitamin A is preferably used in a quantity of from about 0.1 to 0.4 milligrams per liter. Vitamin E is preferably used in quantities of from about 7.5 to 30 milligrams per liter.
Surfactants: In a sufficient quantity to disperse the Vitamins and fatty acids and, thus, provides means to assure availability of the fatty acids and vitamins to the growing cells. A polysorbate 20 is advantageously used.
It is presently believed that the thyroxin, insulin and Vitamin A should be utilized in all embodiments of the invention. Hydrocortisone and essential fatty acids are highly advantageous. Vitamin E is believed to be important in contributing to the versatility of the invention.
One of the problems with developing a serumless tissue culture media comes with passaging, e.g. transferring, the cells between vessels. Proteolytic enzymes (trypsin or the like) will not be neutralized by this kind of media, since a factor present in serum is active in the neutralization process, and can result in damage or death to the cells. Appropriate physical or mechanical means to detach and passage the cells are, therefore, preferable. If proteolytic enzymes become necessary for whatever reason for effective cell detachment, it is suggested that the cells should be washed before replating in media containing enzyme inhibitors which are commercially available. In any event, it is desirable to avoid cell-damaging quantities of enzymes like trypsin in effecting transfer of these serum-free cell populations.
It is to be understood that the various components of the growth media of the invention can be obtained from natural sources when it is convenient to do so. For example, the fatty acids could be made available as processed vegetable oils, e.g. soybean or safflower oil. In such cases, it is necessary to so process the natural material as to remove any substantial quantities of unknown proteinaceous substances.
Although, it is usually preferable to use a zinc-option-type minimum essential medium (MEM) it is possible to achieve a substantial number of the advantages using the invention by appropriate modification of such commercial products known to those skilled in the art, such as Medium 199 Eagle's Basal Medium, Eagle's Minimum Essential Medium or the like.
Illustrative Examples of the Invention
It is, of course, to be understood that the following examples are intended to be illustrative and that numerous changes can be made in the reactants, precise proportions, and conditions set forth therein without departing from the spirit of the invention as defined in the appended claims.
A fortified basic medium formula is prepared according to good preparatory procedures as known in the art.
| ______________________________________ |
| Item Amount (milligrams per liter) |
| ______________________________________ |
| L-alanine 8.9 |
| L-asparagine 75.0 |
| L-aspartic acid |
| 13.0 |
| L-glutamic acid |
| 14.7 |
| L-glycine 7.5 |
| L-proline 11.5 |
| L-serine 52.5 |
| L-arginine HCl |
| 196.52 |
| L-cystine 37.2 |
| L-glutamine 584.0 |
| L-histidine HCl |
| 65.0 |
| L-isoleucine 80.88 |
| L-leucine 160.88 |
| L-lysine 112.38 |
| L-methionine 23.30 |
| L-phenyl-alanine |
| 50.15 |
| L-threonine 74.18 |
| L-tryptophan 15.61 |
| L-valine 71.4 |
| L-tyrosine 45.9 |
| CaCl 200 |
| KCl 400 |
| MgCl6H2 O |
| MgCl2 . 6H2 O |
| 183 |
| MgSO4 7H2 O |
| 12 |
| NaCl 6800 |
| NaH2 PO4 H2 O |
| 150 |
| NaHCO3 sufficient to adjust to a Ph of 7.4 |
| phenol red 10 |
| glucose 2000 |
| Na pyruvate 110 |
| biotin 1.0 |
| D-calcium pantothenate |
| 1.0 |
| choline Cl 56.0 |
| folic acid 1.0 |
| inositol 36.0 |
| nicotinamide 1.0 |
| pyridoxal HCl 1.0 |
| riboflavin 0.1 |
| thiamine 1.0 |
| B12 1.36 |
| folinic acid 1.0 |
| DL thioctic acid |
| 0.20 |
| putrescine HCl |
| 0.16 |
| linoleic 0.084 |
| FeCl3 6H2 O |
| 0.54 |
| ZnSO4 7H2 O |
| 0.14 |
| insulin 4.00 |
| HEPES buffer solution |
| 2380.0 |
| ______________________________________ |
| Distilled water to make a total of 1 liter |
In general, the quantities of ingredients set out above can be modified by about plus-or-minus 20%; which modifications are to be construed to be "about" those required to function as does the listed formula.
HEPES buffer solution is the name given to buffer solutions containing N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid. It has a pKa value of about 7.5.
The aforesaid basic media was used in Example 1 set forth below.
Table 1C illustrates the advantageous characteristics of this basic medium when it is compared to
A. the improved fortified basic media of the invention both with and without the addition of 10% fetal calf serum;
B. a commerically available zinc-option-bearing MEM formula sold under the trade designation IMEMZO & HEPES by Associated Biomedic Systems, Inc., of Buffalo, N.Y. Again, the comparison was carried out with and without augmentation of the formula with 10% fetal calf serum.
The drawing is indicative of the cell growth in terms of thimidine radioactive count (TRC) as follows:
| TABLE 1C |
| ______________________________________ |
| Growth Media and Cell History |
| Count |
| ______________________________________ |
| IMEMZO & HEPES, no serum-cell line |
| nil |
| IMEMZO & HEPES, no serum initial culture |
| nil |
| Basic Media of Invention, no serum-initial culture |
| 1,533 |
| Basic Media of Invention, no serum-cell line culture |
| 54,672 |
| Basic Media of Invention, serum-cell line culture |
| 20,825 |
| Basic Media of Invention, serum-initial culture |
| 8,293 |
| ______________________________________ |
"Initial culture" is used to define the primary tumor cells. "Cell line" is used to define cells grown on tissue culture flask for a minimum of five passages.
It will be readily seen that the Basic Media of the invention is superior in cell-line culturing procedures, not only to media with different fully-characterized profiles (IMEMZO) but to itself when fetal calf serum is incorporated therein.
The results disclosed in Example 1 were obtained according to the following procedure:
The tumor cells used in this experiment were rhabdomyosarcoma of mice, Balb-C strain, produced in the laboratory by the intramuscular injection of methylcholanthrene in experimental animals. The tumor was observed to form within several weeks of injection. This tumor was subcultured and kept by serial passage within a line of Balb-C mice and in serum supplemented tissue culture media by different researchers.
A suspension of viable cells were injected subcutaneously in Balb-C mice (from Charles River Breeding Labs) in a concentration of 1,000,000 viable cells per injection. Tumor growth was carefully monitored in these mice.
Cells obtained from these tumors may be classified in several different fashions. "Primary tumor cells" define cells obtained by the disperion of the tumor grown anew, fresh, in a Balb-C mouse. These cells were separated from the tumor, by the use of standard trypsinization techniques. Trypsin was neutralized with serum and the cells were washed before further use. Their viability was assayed by the trypan blue technique. These cells are labelled as "Primary Tumor Cells."
Cell lines were cultured in tissue culture media from these primary tumor cells by using basic media, as described in the body of this disclosure, e.g. Example 1. However, this basic media used to establish the cell lines contained 10% (by volume) of fetal calf serum. Prior to use of these cell lines, the cells were again dispersed by the cold-media technique described below and their viability checked by the trypan blue technique. These cells are referred to herein as "cell lines."
Transferring of the cells between vessels, in multipassages work is accomplished by adding cold media (about 4°C) to the flask followed by shaking and dispersion by vortexing. In this way the cells are cold shocked and readily released for transfer way the cells are cold shocked and readily released for transfer to a new vessel and a new passage
The following procedure is used to test for the activity of the different growth media formulations:
The growth of cells was estimated by the amount of incorporation of radioactively labelled (tritium labelled) thimidine. Thimidine is incorporated by growing cells for the manufacture of DNA. Thus, the amount of radioactivity incorporated into growing cells incubated in radiactively labelled thimidine directly approximates the growth that has taken place within the cell culture. Cells were grown in this fashion using each of stock-IMEMZO and the basic medium of the invention. For each medium, experiments were carried out with media containing 10% (by volume) fetal calf serum and media containing no serum.
Incorporation of radioactively labelled thimidine by primary tumor cells and cell lines grown in stock-IMEMZO media either with or without fetal calf serum supplementation, is nil or not significantly different than the background radioactive count. Primary cells grown in basic media with no serum supplementation shows an incorporation of 1,533 radioactive counts. Primary cells grown in basic media with 10% fetal calf serum supplementation showed an incorporation of 8,293 counts.
The cell line, as described above, is a primary tumor cell that has been serially grown in vitro for a minimum of 5 passages. A passage being defined as that period of time it takes for the cells to form a monolayer. This is followed by dispersion of this monolayer and reculturing of cell aliguots in a fresh flask.
Testing of the cell lines resulted in markedly different results. The cell line grown in stock-IMEMZO media with or without serum supplementation again was unable to incorporate radioactivity to any appreciable extent. The cell line grown in basic media with no serum supplementation showed an incorporation of 54,672 counts on the average. The cell line grown in basic media supplemented with 10% fetal calf serum showed an incorporation of only 20,825 counts.
In all cases, the cells were incubated for three days at 37°C in a 5% CO2 atmosphere before they were exposed to radioactively labelled thimidine for 12 hours and then counted again. In each case, quadruplicate culutures of 105 viable cells were carried out by use of a microtiter plate culturing system. These cells were processed for counting with an automatic harvesting machine and counted in a Searle liquid scintillation counter.
The numbers given for incorporation of radio active counts represent the average number of counts per minute per culture, counted by the liquid scintillation apparatus. All the cells present in each culture were harvested and the total radioactive content of the complete population of cells in each culture yielded the radioactive counts expressed above as an average. Each different type of culture (determined by the media used, the cell type and the presence or absence of fetal calf serum in the media) yielded, therefore, its own average count.
The following conclusions may be derived from the experiments above:
1. Stock-IMEMZO, either with or without serum supplementation, is unable to support the growth of these cells in vitro.
2. Basic medium with a 10% fetal calf serum supplementation is better than the same media without serum supplementation in supporting the growth of primary cells in vitro.
3. Basic medium with no serum supplementation supports the in vitro growth of cell lines up to 250% better than basic medium with 10% serum supplementation.
Basic medium without serum supplementation seems to be clearly superior to the same medium with 10% fetal calf serum supplementation in growing cell lines in vitro. Thereby it provides a medium able to sustain cell lines in vitro without the use of serum or other bulk biological products.
To test the abiliy of the basic medium to sustain the growth of cell lines for extended periods of time, the cell lines described above were grown in basic medium, free of serum supplementation, for a period of five months. The changeover to serumless medium was accomplished gradually, over 2 weeks. The cells were observed to clump initially, but soon afterwards they regained their normal morphology and were observed to form monolayers and grow as well as the control cell lines kept in media supplemented with 10% fetal calf serum. Thus, the basic medium was clearly successful in supporting the growth of these cell lines. At this point it was decided to terminate these experiments with methylcholanthrene induced rhabdomyosarcoma cell lines and to start testing various other cell lines for their growth in this media.
To the above basic media were added the following:
| ______________________________________ |
| Item Amount |
| ______________________________________ |
| thyroxine 0.02 micrograms per liter |
| insulin 4 milligrams per liter |
| hydrocortisone 1.5 #x2205;15 |
| milligrams per liter |
| linoleic acid 5.0 milligrams per liter |
| linolenic acid 5.0 milligrams per liter |
| arachidonic acid 5.0 milligrams per liter |
| surfactant, emulsifier* |
| 110 milligrams per liter |
| Vitamin E 20 milligrams per liter |
| Vitamin A 0.25 milligrams per liter |
| ______________________________________ |
The surfactant is a micelle-forming material sold by Supelco Co. under the trade designation Tween 20. The material is characterized by its ability to emulsify, or isolate and expose, molecules of fatty acids in small micelle-type structures thereby making them readily dispersible in aqueous solutions and available to the growing cells. Any other surfactant which achieves this effect with a reasonable concentration and is not otherwise detrimental to cell growth may also be utilized.
The procedure of Example 1 is used to demonstrate the advantage of the above-described culture media. Excellent results are achieved with cell lines.
The following certified cell lines, all available in the American-type Culture Collection at Rockville, Md., are also advantageously grown in the growth medium of Example 2, and then counted according to the procedure set forth therein:
MRC--Human embryonic lung cell line.
L929--Mouse fibrosarcoma line.
Vero--African green monkey kidney line.
It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which might be said to fall therebetween.
| Patent | Priority | Assignee | Title |
| 10000571, | Mar 25 2009 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| 10005847, | May 27 2014 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
| 10010611, | Mar 13 2013 | Genentech, Inc. | Antibody formulations |
| 10011856, | May 28 2010 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
| 10017732, | Mar 15 2013 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
| 10023892, | May 27 2014 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| 10086054, | Jun 26 2013 | Academia Sinica | RM2 antigens and use thereof |
| 10087236, | Dec 02 2009 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| 10087255, | Apr 07 2015 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| 10106600, | Mar 26 2010 | ROCHE GLYCART AG | Bispecific antibodies |
| 10106612, | Jun 27 2012 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| 10111951, | Sep 06 2013 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| 10113193, | Mar 31 2015 | NOVIMMUNE S A | Method for optimizing the assembly and production of hetero-multimeric protein complexes |
| 10118969, | May 27 2014 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| 10119972, | Mar 27 2014 | Academia Sinica | Reactive labelling compounds and uses thereof |
| 10130714, | Apr 14 2012 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| 10131873, | Mar 15 2013 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
| 10144944, | Mar 14 2013 | MOMENTA PHARMACEUTICALS, INC. | Methods of cell culture |
| 10150818, | Jan 16 2014 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| 10183983, | Mar 13 2013 | Genzyme Corporation | Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof |
| 10183996, | Feb 28 2014 | ALLAKOS INC | Methods and compositions for treating Siglec-8 associated diseases |
| 10202616, | Oct 15 2014 | Amgen Inc | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
| 10208120, | Nov 05 2014 | F HOFFMANN-LA ROCHE AG | Anti-FGFR2/3 antibodies and methods using same |
| 10214765, | Aug 18 2012 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| 10253101, | Aug 06 2015 | XOMA US LLC | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| 10266589, | Jul 29 2015 | Allergan, Inc | Heavy chain only antibodies to ANG-2 |
| 10274488, | Jul 15 2008 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
| 10287356, | Mar 25 2009 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| 10308711, | Aug 14 2015 | Allergan, Inc | Heavy chain only antibodies to PDGF |
| 10308718, | Apr 07 2016 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| 10317393, | Mar 23 2007 | Academia Sinica | Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells |
| 10336784, | Mar 08 2016 | Academia Sinica | Methods for modular synthesis of N-glycans and arrays thereof |
| 10338069, | Apr 12 2010 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| 10342858, | Jan 24 2015 | Academia Sinica | Glycan conjugates and methods of use thereof |
| 10364268, | Dec 22 2011 | Genentech, Inc. | Ion exchange membrane chromatography |
| 10428150, | Apr 07 2015 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| 10495645, | Jan 16 2015 | Academia Sinica | Cancer markers and methods of use thereof |
| 10525137, | Dec 30 2015 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
| 10533034, | Sep 08 2014 | Academia Sinica | Human iNKT cell activation using glycolipids |
| 10538592, | Aug 22 2016 | OBI PHARMA INC ; CHO PHARMA INC | Antibodies, binding fragments, and methods of use |
| 10602739, | Jul 09 2014 | Genentech, Inc. | PH adjustment to improve thaw recovery of cell banks |
| 10604577, | Oct 22 2015 | ALLAKOS INC | Methods and compositions for treating systemic mastocytosis |
| 10611795, | Nov 15 2013 | Genentech, Inc. | Methods for viral inactivation using eco-friendly detergents |
| 10618973, | May 27 2014 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
| 10626189, | Oct 11 2011 | Genentech, Inc. | Assembly of bispecific antibodies |
| 10633457, | Dec 03 2014 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| 10653779, | Mar 13 2013 | Genentech, Inc | Formulations with reduced oxidation |
| 10676710, | Mar 15 2013 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
| 10704071, | May 28 2010 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
| 10711067, | Mar 03 2015 | XOMA (US) LLC; XOMA US LLC | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| 10730951, | Mar 31 2014 | Genentech, Inc. | Anti-OX40 antibodies and methods of use |
| 10774145, | Jun 17 2015 | ALLAKOS INC | Methods and compositions for treating fibrotic diseases |
| 10822416, | Mar 23 2016 | MABSPACE BIOSCIENCES SUZHOU CO , LTD | Anti-PD-L1 antibodies |
| 10829732, | Mar 15 2013 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
| 10844122, | May 06 2015 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
| 10849992, | Apr 07 2015 | Alector LLC | Methods of screening for sortilin binding antagonists |
| 10865248, | Apr 07 2015 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| 10918714, | Sep 06 2013 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| 10925932, | Jun 03 2016 | Janssen Biotech, Inc. | Serum albumin-binding fibronectin type III domains |
| 10925966, | Mar 13 2013 | Genentech, Inc. | Antibody formulations |
| 10927144, | Aug 14 2008 | Genentech, Inc | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography |
| 10927342, | Aug 04 2015 | Regeneran Pharmaceuticals, Inc. | Taurine supplemented cell culture medium and methods of use |
| 10933141, | Dec 30 2015 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
| 10935544, | Sep 04 2015 | OBI PHARMA, INC.; OBI PHARMA, INC | Glycan arrays and method of use |
| 10941190, | May 06 2014 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
| 10941203, | Mar 15 2017 | Tsinghua University | Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma |
| 10947297, | Apr 13 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind PCSK9 |
| 10947531, | Aug 10 2012 | CYTOMX THERAPEUTICS, INC. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| 10975168, | Nov 02 2015 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| 10980894, | Mar 29 2016 | OBI PHARMA, INC. | Antibodies, pharmaceutical compositions and methods |
| 11000601, | Nov 21 2016 | OBI PHARMA, INC | Conjugated biological molecules, pharmaceutical compositions and methods |
| 11008391, | Aug 11 2015 | WuXi Biologics Ireland Limited | Anti-PD-1 antibodies |
| 11028163, | Aug 14 2015 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
| 11034793, | Mar 25 2014 | Genentech, Inc. | Methods of preparing a poloxamer for use in cell culture medium |
| 11041017, | Mar 29 2016 | OBI PHARMA, INC | Antibodies, pharmaceutical compositions and methods |
| 11043823, | Apr 06 2017 | TESLA, INC | System and method for facilitating conditioning and testing of rechargeable battery cells |
| 11046756, | Jul 29 2015 | Allergan, Inc. | Heavy chain only antibodies to ANG-2 |
| 11046776, | Aug 05 2016 | F HOFFMANN-LA ROCHE AG | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| 11078464, | Aug 30 2013 | Amgen Inc | High titer recombinant AAV vector production in adherent and suspension cells |
| 11084864, | Mar 13 2013 | Genzyme Corporation | Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof |
| 11091551, | Oct 05 2012 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| 11096998, | Sep 14 2016 | JANSSEN BIOTECH, INC | Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof |
| 11111313, | Sep 20 2016 | WuXi Biologics Ireland Limited | Anti-PCSK9 antibodies |
| 11116840, | Apr 24 2015 | Genentech, Inc. | Multispecific antigen-binding proteins |
| 11161897, | Jul 17 2017 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
| 11186645, | Apr 07 2015 | Alector LLC | Isolated nucleic acids encoding anti-sortilin antibodies |
| 11198864, | Aug 10 2012 | CYTOMX THERAPEUTICS, INC. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| 11203638, | May 05 2017 | ALLAKOS INC | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
| 11203645, | Jun 27 2018 | OBI PHARMA, INC. | Glycosynthase variants for glycoprotein engineering and methods of use |
| 11208488, | Apr 07 2015 | Alector LLC | Methods of increasing progranulin levels using anti-Sortilin antibodies |
| 11213613, | Jun 12 2015 | Institute of Genetics and Developmental Biology, Chinese Academy of Sciences | Three-dimensional tissue scaffold with stem cell attracting element and use thereof |
| 11242404, | Sep 21 2016 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| 11254987, | May 29 2015 | Genentech, Inc. | PD-L1 promoter methylation in cancer |
| 11267870, | Dec 02 2009 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| 11270782, | Nov 19 2014 | P & M VENGE AB | Diagnostic method employing HNL |
| 11292850, | Mar 21 2018 | ALX ONCOLOGY INC | Antibodies against signal-regulatory protein α and methods of use |
| 11312936, | Aug 04 2015 | REGENERON PHARMACEUTICALS, INC | Taurine supplemented cell culture medium and methods of use |
| 11319567, | May 27 2014 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| 11332523, | May 28 2014 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
| 11332771, | Mar 15 2013 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
| 11339223, | Apr 07 2015 | Alector LLC | Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury |
| 11365239, | Mar 20 2020 | TSB THERAPEUTICS BEIJING CO , LTD | Anti-SARS-COV-2 antibodies and uses thereof |
| 11370833, | Sep 15 2014 | Genentech, Inc. | Antibody formulations |
| 11377485, | Dec 02 2009 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| 11390668, | Oct 20 2009 | AbbVie Inc. | Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography |
| 11396546, | Jul 13 2018 | Alector LLC | Anti-Sortilin antibodies and methods of use thereof |
| 11401333, | Mar 25 2009 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| 11401338, | Sep 21 2016 | CRYSTAL BIOSCIENCE INC | Antibodies against signal-regulatory protein alpha and methods of use |
| 11407836, | Jun 27 2012 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| 11421022, | Jun 27 2012 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| 11447573, | Jul 20 2016 | NANJING LEGEND BIOTECH CO , LTD | Multispecific antigen binding proteins and methods of use thereof |
| 11472881, | Oct 11 2016 | NANJING LEGEND BIOTECH CO , LTD | Single-domain antibodies and variants thereof against CTLA-4 |
| 11485782, | Mar 14 2018 | BEIJING XUANYI PHARMASCIENCES CO , LTD | Anti-claudin 18.2 antibodies |
| 11518984, | Dec 01 2011 | AP Biosciences, Inc.; INNOVENT BIOLOGIS, INC. | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
| 11583577, | Apr 22 2016 | OBI PHARMA, INC | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
| 11591382, | Sep 22 2015 | Genentech, Inc. | Expression of Fc-containing proteins |
| 11596620, | Mar 13 2013 | F. Hoffmann-La Roche AG | Formulations with reduced oxidation |
| 11618790, | Dec 23 2010 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| 11642400, | Jul 27 2016 | OBI PHARMA, INC | Immunogenic/therapeutic glycan compositions and uses thereof |
| 11643456, | Jul 29 2016 | OBI PHARMA, INC | Human antibodies, pharmaceutical compositions and methods |
| 11643465, | Aug 11 2015 | WuXi Biologics Ireland Limited | Anti-PD-1 antibodies |
| 11661452, | Mar 20 2018 | WuXi Biologics Ireland Limited; CSTONE PHARMACEUTICALS; CSTONE PHARMACEUTICALS SUZHOU CO , LTD ; CSTONE PHARMACEUTICALS SHANGHAI CO , LTD | Anti-lag-3 antibody polypeptide |
| 11667949, | Feb 15 2018 | The Trustees of Princeton University | Reporter construct and biosensor for interferon second messenger 2-5A |
| 11713353, | Jan 15 2018 | NANJING LEGEND BIOTECH CO , LTD | Single-domain antibodies and variants thereof against PD-1 |
| 11725065, | Oct 11 2011 | Genentech, Inc. | Assembly of bispecific antibodies |
| 11753473, | Mar 23 2016 | SUZHOU TRANSCENTA THERAPEUTICS CO , LTD | Anti-PD-L1 antibodies |
| 11802165, | Nov 02 2015 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| 11833190, | Jun 03 2016 | Janssen Biotech, Inc. | Serum albumin-binding fibronectin type III domains |
| 11833223, | Mar 29 2016 | OBI PHARMA, INC. | Antibodies, pharmaceutical compositions and methods |
| 11834683, | Aug 30 2013 | Amgen Inc | High titer recombinant AAV vector production in adherent and suspension cells |
| 11858979, | Apr 13 2010 | Bristol-Meyers Squibb Company | Fibronectin based scaffold domain proteins that bind PCSK9 |
| 11866476, | Sep 27 2018 | Xilio Development, Inc. | Masked IL-2-Fc fusion polypeptides |
| 11884739, | May 27 2014 | Academia Sinica | Anti-CD20 glycoantibodies and uses thereof |
| 11905327, | Dec 28 2017 | NANJING LEGEND BIOTECH CO , LTD | Single-domain antibodies and variants thereof against TIGIT |
| 11912754, | Oct 12 2017 | IMMUNOWAKE INC | VEGFR-antibody light chain fusion protein |
| 11912823, | Mar 25 2014 | Genentech, Inc. | Methods of preparing a poloxamer for use in cell culture medium |
| 4560655, | Dec 16 1982 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| 4615977, | Dec 24 1981 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for the cultivation of normal diploid cells and cultivation medium used therefor |
| 4663289, | Jun 22 1984 | BTG International Limited | Electrolyte solutions and in vitro use thereof |
| 4757018, | Feb 11 1985 | Hazleton Biotechnologies, Inc. | Myeloma cell lines and uses thereof |
| 4786599, | Mar 24 1983 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium |
| 5110722, | Nov 09 1989 | HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT | Cell, tissue or organ storage solution |
| 5122469, | Oct 03 1990 | Genentech, Inc.; Genentech, Inc | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| 5342777, | Dec 14 1988 | The United States of America as represented by the Secretary of the | Cell culture medium for human liver epithelial cell line |
| 5372943, | Jul 24 1987 | Chiron Corporation | Lipid microemulsions for culture media |
| 5529920, | Dec 14 1988 | The United States of America as represented by the Secretary of the | Human liver epithelial cell line and culture media therefor |
| 5851984, | Aug 16 1996 | Genentech, Inc | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| 6159462, | Aug 16 1996 | Genentech, Inc | Uses of Wnt polypeptides |
| 6270987, | Jan 31 1997 | Genentech, Inc. | O-fucosyltransferase |
| 6767741, | Aug 27 1999 | Life Technologies Corporation | Metal binding compounds and their use in cell culture medium compositions |
| 7138512, | Apr 10 2002 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| 7244565, | Apr 10 2002 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| 7250298, | Apr 07 2004 | The University of Washington | Monomeric red fluorescent proteins |
| 7253272, | Apr 06 2001 | Georgetown University | Gene BRCC-2 and diagnostic and therapeutic uses thereof |
| 7442520, | Apr 06 2001 | Georgetown University | Gene BRCC-3 and diagnostic and therapeutic uses thereof |
| 7537885, | May 07 2004 | NEW GROVE INVESTMENTS, INC | Composition for maintaining organ and cell viability |
| 7575893, | Jan 23 2003 | Genentech, Inc | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| 7597884, | Aug 09 2004 | ALIOS BIOPHARMA, INC | Hyperglycosylated polypeptide variants and methods of use |
| 7671185, | Apr 07 2004 | The University of Chicago; The University of Washington | Monomeric red fluorescent proteins |
| 7705195, | Jun 07 2002 | Genentech, Inc | Screening method |
| 7741096, | Dec 10 2004 | Genentech, Inc | Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor |
| 7749704, | Nov 01 2005 | ZYMOGENETICS, INC; Mayo Foundation for Medical Education and Research | Promoter polymorphisms of the BLyS gene and use in diagnostic methods |
| 7754458, | May 06 2004 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use |
| 7794713, | Oct 28 2004 | APOLLO ENDOSURGERY, INC | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| 7862812, | May 31 2006 | APOLLO ENDOSURGERY, INC | Methods for decreasing immune response and treating immune conditions |
| 7906625, | Jan 24 2005 | Amgen Inc | Humanized anti-amyloid antibody |
| 7910714, | Apr 07 2004 | The University of Chicago; The University of Washington | Monomeric red fluorescent proteins |
| 8003325, | Nov 30 2007 | Mayo Foundation for Medical Education and Research | Polymorphisms of the BLyS gene and use in diagnostic methods |
| 8158124, | May 30 2007 | APOLLO ENDOSURGERY, INC | Compositions and methods for binding lysophosphatidic acid |
| 8216807, | Oct 12 2006 | Genentech, Inc. | Antibodies to lymphotoxin-α |
| 8222373, | Oct 27 2006 | APOLLO ENDOSURGERY, INC ; Boston Scientific Scimed, Inc | Humanized antibodies and compositions for binding sphingosine-1-phosphate |
| 8236315, | Jan 23 2008 | Ichnos Sciences SA | Humanized antibodies specific for von Willebrand factor |
| 8298531, | Nov 06 2008 | Ichnos Sciences SA | Treatment with anti-alpha2 integrin antibodies |
| 8361465, | Oct 26 2007 | APOLLO ENDOSURGERY, INC | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| 8410250, | Mar 25 2009 | F HOFFMANN-LA ROCHE AG | Anti-FGFR3 antibodies and methods using same |
| 8414893, | Dec 21 2007 | Amgen Inc | Anti-amyloid antibodies and uses thereof |
| 8420098, | Apr 13 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to PCSK9 |
| 8541552, | Oct 12 2006 | Genetech, Inc. | Antibodies to lymphotoxin-α |
| 8629250, | Feb 02 2007 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use |
| 8642740, | Oct 12 2006 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
| 8664471, | Dec 19 2001 | The University of Washington | Rapidly maturing fluorescent proteins and methods for using the same |
| 8679490, | Nov 07 2005 | Genentech, Inc | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| 8679749, | Nov 01 2007 | The University of Chicago | Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| 8710189, | Mar 25 2009 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| 8759491, | Oct 19 2009 | F HOFFMAN-LA ROCHE AG | Modulators of hepatocyte growth factor activator |
| 8765431, | Jul 23 2009 | The Regents of the University of Michigan | Method for enzymatic production of decarboxylated polyketides and fatty acids |
| 8771685, | Dec 23 2009 | Genentech, Inc; F HOFFMANN-LA ROCHE AG | Anti-BV8 antibodies and uses thereof |
| 8771966, | Jun 03 2010 | F HOFFMANN-LA ROCHE AG | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
| 8871202, | Oct 24 2008 | APOLLO ENDOSURGERY, INC ; Boston Scientific Scimed, Inc | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| 8927693, | Feb 18 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
| 8956830, | Mar 14 2013 | MOMENTA PHARMACEUTICALS, INC | Methods of cell culture |
| 8957187, | Dec 02 2005 | Genentech, Inc | Binding polypeptides and uses thereof |
| 9000132, | Mar 15 2013 | DIAZYME LABORATORIES, INC | Lipoprotein-associated phospholipase A2 antibody compositions and methods of use |
| 9062106, | Apr 27 2011 | ABBVIE, INC | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| 9067990, | Mar 14 2013 | ABBVIE, INC | Protein purification using displacement chromatography |
| 9090688, | Apr 27 2011 | AbbVie Inc | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| 9150645, | Apr 20 2012 | AbbVie Inc | Cell culture methods to reduce acidic species |
| 9161977, | Mar 25 2009 | F. Hoffmann-La Roche AG | Anti-FGFR3 antibodies and methods using same |
| 9163091, | May 30 2007 | Boston Scientific Scimed, Inc; APOLLO ENDOSURGERY, INC | Compositions and methods for binding lysophosphatidic acid |
| 9170262, | Jun 16 2010 | AbbVie Inc | Comparison of protein samples |
| 9175078, | Jan 25 2008 | Amgen Inc | Ferroportin antibodies and methods of use |
| 9181337, | Oct 18 2013 | AbbVie Inc | Modulated lysine variant species compositions and methods for producing and using the same |
| 9181572, | Apr 20 2012 | AbbVie Inc | Methods to modulate lysine variant distribution |
| 9193787, | Apr 20 2012 | ABBVIE, INC | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| 9200069, | Oct 18 2013 | AbbVie, Inc. | Low acidic species compositions and methods for producing and using the same |
| 9200070, | Oct 18 2013 | AbbVie, Inc. | Low acidic species compositions and methods for producing and using the same |
| 9206390, | Sep 02 2012 | ABBVIE, INC | Methods to control protein heterogeneity |
| 9217168, | Mar 14 2013 | JANSSEN BIOTECH, INC | Methods of cell culture |
| 9234027, | Apr 13 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind PCSK9 |
| 9234033, | Sep 02 2012 | AbbVie, Inc. | Methods to control protein heterogeneity |
| 9249182, | May 24 2012 | ABBVIE, INC | Purification of antibodies using hydrophobic interaction chromatography |
| 9255143, | Apr 27 2011 | ABBVIE, INC | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| 9266948, | Dec 23 2009 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
| 9266949, | Oct 18 2013 | AbbVie, Inc. | Low acidic species compositions and methods for producing and using the same |
| 9266950, | Oct 20 2009 | AbbVie Inc. | Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography |
| 9290568, | Sep 02 2012 | AbbVie, Inc. | Methods to control protein heterogeneity |
| 9309510, | Aug 10 2012 | CYTOMX THERAPEUTICS, INC | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| 9315574, | Oct 18 2013 | AbbVie, Inc. | Low acidic species compositions and methods for producing and using the same |
| 9334319, | Apr 20 2012 | AbbVie Inc | Low acidic species compositions |
| 9346879, | Apr 20 2012 | AbbVie Inc. | Protein purification methods to reduce acidic species |
| 9359434, | Apr 20 2012 | AbbVie, Inc. | Cell culture methods to reduce acidic species |
| 9365645, | Apr 27 2011 | AbbVie, Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| 9382323, | Apr 02 2009 | Hoffmann-La Roche Inc | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| 9403855, | May 10 2010 | Academia Sinica | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| 9405884, | Jun 16 2010 | AbbVie Inc | Methods and systems for the analysis of protein samples |
| 9428548, | Sep 01 2009 | Genentech, Inc | Enhanced protein purification through a modified protein A elution |
| 9465029, | Apr 16 2004 | Glaxo Group Limited | Methods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activity |
| 9487809, | May 28 2010 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
| 9487810, | Mar 14 2013 | MOMENTA PHARMACEUTICALS, INC. | Methods of cell culture |
| 9493744, | Jun 20 2012 | F HOFFMANN-LA ROCHE AG | Methods for viral inactivation and other adventitious agents |
| 9499614, | Mar 14 2013 | AbbVie Inc | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| 9499616, | Oct 18 2013 | AbbVie Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| 9499623, | Mar 25 2009 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| 9505833, | Apr 20 2012 | AbbVie Inc | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| 9505834, | Apr 27 2011 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| 9512214, | Sep 02 2012 | ABBVIE, INC | Methods to control protein heterogeneity |
| 9522953, | Oct 18 2013 | AbbVie, Inc. | Low acidic species compositions and methods for producing and using the same |
| 9546215, | Dec 09 2013 | ALLAKOS INC | Anti-Siglec-8 antibodies and methods of use thereof |
| 9547009, | Aug 21 2012 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| 9550826, | Nov 15 2013 | AbbVie Inc. | Glycoengineered binding protein compositions |
| 9562097, | Jul 01 2011 | F HOFFMANN-LA ROCHE AG | Use of anti-CD83 agonist antibodies for treating autoimmune diseases |
| 9598667, | Oct 04 2013 | ABBVIE, INC | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| 9637534, | Mar 13 2013 | Genzyme Corporation | Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof |
| 9637557, | Apr 23 2010 | F HOFFMANN LA-ROCHE AG | Production of heteromultimeric proteins |
| 9663810, | Mar 14 2013 | JANSSEN BIOTECH, INC | Methods of cell culture |
| 9677105, | Mar 14 2013 | MOMENTA PHARMACEUTICALS, INC | Methods of cell culture |
| 9683033, | Apr 20 2012 | AbbVie, Inc. | Cell culture methods to reduce acidic species |
| 9688752, | Oct 18 2013 | AbbVie Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| 9688758, | Feb 10 2012 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| 9688759, | Jan 25 2008 | Amgen, Inc. | Ferroportin antibodies and methods of use |
| 9688775, | Aug 27 2001 | Genentech, Inc. | System for antibody expression and assembly |
| 9708399, | Mar 14 2013 | AbbVie, Inc. | Protein purification using displacement chromatography |
| 9708400, | Apr 20 2012 | AbbVie, Inc. | Methods to modulate lysine variant distribution |
| 9714281, | Feb 18 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
| 9738702, | Mar 14 2014 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
| 9759726, | Mar 27 2014 | Academia Sinica | Reactive labelling compounds and uses thereof |
| 9782476, | Sep 06 2013 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| 9816981, | Mar 23 2007 | Academia Sinica | Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells |
| 9821065, | Mar 13 2013 | Genentech, Inc. | Antibody formulations |
| 9856309, | Apr 13 2010 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind PCSK9 |
| 9862778, | Oct 11 2011 | Genentech, Inc. | Assembly of bispecific antibodies |
| 9873742, | Oct 05 2012 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| 9874562, | May 10 2010 | Academia Sinica | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| 9879042, | Sep 08 2014 | Academia Sinica | Human iNKT cell activation using glycolipids |
| 9879095, | Aug 24 2010 | Hoffmann-La Roche Inc | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
| 9914956, | Aug 18 2012 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| 9926583, | Mar 14 2013 | MOMENTA PHARMACEUTICALS, INC. | Methods of cell culture |
| 9957318, | Apr 20 2012 | AbbVie Inc. | Protein purification methods to reduce acidic species |
| 9975948, | Oct 20 2009 | AbbVie, Inc. | Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography |
| 9975957, | Mar 31 2014 | F HOFFMANN-LA ROCHE AG | Anti-OX40 antibodies and methods of use |
| 9975965, | Jan 16 2015 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| 9981030, | Jun 27 2013 | Academia Sinica | Glycan conjugates and use thereof |
| 9982041, | Jan 16 2014 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| 9988611, | Dec 01 2011 | AP BIOSCIENCES, INC | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
| 9994646, | Sep 16 2009 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| Patent | Priority | Assignee | Title |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Jun 29 1985 | 4 years fee payment window open |
| Dec 29 1985 | 6 months grace period start (w surcharge) |
| Jun 29 1986 | patent expiry (for year 4) |
| Jun 29 1988 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 29 1989 | 8 years fee payment window open |
| Dec 29 1989 | 6 months grace period start (w surcharge) |
| Jun 29 1990 | patent expiry (for year 8) |
| Jun 29 1992 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 29 1993 | 12 years fee payment window open |
| Dec 29 1993 | 6 months grace period start (w surcharge) |
| Jun 29 1994 | patent expiry (for year 12) |
| Jun 29 1996 | 2 years to revive unintentionally abandoned end. (for year 12) |